Table 1.
Clinical parameters of study patients.
| Clinical parameters | n = 33 |
|---|---|
| Median age (range) | 57 (37–79) |
| Sex (male), n (%) | 25 (75.8) |
| HBsAg-positivity, n (%) | 29 (87.9) |
| Anti-HCV-positivity, n (%) | 1 (3) |
| Median tumor size, cm | 3.5 |
| <5 cm, n (%) | 21 (64) |
| ≥5 cm, n (%) | 12 (36) |
| Multiple tumors, n (%) | 33 (100) |
| Portal vein tumor thrombosis, n (%) | 10 (30) |
| Extrahepatic metastasis, n (%) | 26 (79) |
| BCLC stage B/C, n (%) | 4/29 (12/88) |
| Median AFP (range), ng/mL | 665 (1.3–160000) |
| <1000 ng/mL, n (%) | 17 (52) |
| ≥1000 ng/mL, n (%) | 16 (49) |
| Child–Pugh score | |
| 5, n (%) | 20 (61) |
| 6, n (%) | 6 (18) |
| 7, n (%) | 7 (21) |
| ALBI grade 1/2/3, n (%) | 15/18/0 (45/55/0) |
| Prior therapy to nivolumab, n (%) | |
| Surgical resection | 12 (36) |
| TACE / TARE | 26 (79) |
| HAIC | 5 (15) |
| Sorafenib | 31 (94) |
| Regorafenib | 13 (39) |
| Lenvatinib | 2 (6) |
| Post nivolumab treatment, n (%) | |
| No treatment | 21 (64) |
| Resection | 1 (3) |
| TACE | 2 (6) |
| Radiation therapy | 3 (9) |
| Regorafenib | 2 (6) |
| Cabozantinib | 2 (6) |
| HAIC | 1 (3) |
| Systemic chemotherapy | 2 (6) |
| Best responses to nivolumab | |
| Complete response | 2 (6) |
| Partial response | 4 (12) |
| Stable disease | 4 (12) |
| Progressive disease | 19 (58) |
| Not assessed | 4 (12) |
AFP, alpha fetoprotein; ALBI grade, albumin-bilirubin grade; BCLC stage, Barcelona-Clinic liver cancer stage; HAIC, hepatic arterial infusion chemotherapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C; RT, radiotherapy; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.